NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
Clinical Trials
13 trialsNCT02994784 2023-05-24
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Boston Medical Center
Phase 2 Terminated
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00651937 2020-01-14
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00681044 2017-04-28
HD Melphalan and SCT in Patients With IGDD or LCDD
Boston Medical Center
Phase 2 Terminated
NCT00679367 2017-02-20
MRD
Boston Medical Center
Phase 2 Completed
NCT00790647 2017-02-06
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00075608 2017-01-27
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Phase 2 Terminated
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed